{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:17:20Z","timestamp":1772986640729,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:00:00Z","timestamp":1339459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:00:00Z","timestamp":1339459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Kaohsiung J of Med Scie"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      To assess the effect of alfuzosin (XATRAL) 10\u2009mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) &gt;8 (range of scores, 0\u201335), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10\u2009mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function\u2014five\u2010item version (range of scores: 5\u201325), as well as onset of action and peak urinary flow rate (\n                      <jats:italic>Q<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and the IPSS bother score (3.8 vs. 2.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The majority (85%) of patients perceived an improvement of urinary symptoms within 1 month of administration. In patients with an International Index of Erectile Function\u2014five\u2010item version score of \u226416, alfuzosin significantly improved erectile disorder and satisfaction subscores at each time point (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.02). Prolonged\u2010release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the management of patients with BPH\/LUTS and concomitant sexual dysfunction.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.kjms.2012.02.013","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T17:31:22Z","timestamp":1339522282000},"page":"429-434","source":"Crossref","is-referenced-by-count":4,"title":["Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia"],"prefix":"10.1002","volume":"28","author":[{"given":"Thomas I.S.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng\u2010Hsien","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao\u2010Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih\u2010Shou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang\u2010Ming","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong\u2010Chiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shauh\u2010Der","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen\u2010Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po\u2010Hui","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry S.J.","year":"1984","journal-title":"J Urol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000049886"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80304-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14681990412331317890"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08503.x"},{"issue":"1","key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/sj.pcan.4500541","article-title":"Impact of treatment of BPH on sexuality","volume":"4","author":"Schulman C.","year":"2001","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"e_1_2_6_8_2","first-page":"19","article-title":"Quality of life in sexually active men with symptomatic benign prostatic hyperplasia. Effects of treatment","volume":"25","author":"Daly M.P.","year":"2005","journal-title":"Clin Drug Investig"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.04.056"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00539-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13762.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)02234-A"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05347.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05456.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05252.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijir.2008.62"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01743.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900472"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.07.016"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA Guidelines on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee","year":"2003","journal-title":"J Urol"},{"key":"e_1_2_6_21_2","first-page":"73","article-title":"Selecting an appropriate \u03b11\u2010adrenoceptor blocker in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"3","author":"Liu C.C.","year":"2009","journal-title":"Incont Pelvic Floor Dysfunct"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7262.2008.00355.x"},{"issue":"2","key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1464-410X.2008.08087.x","article-title":"Medical treatments for benign prostatic hyperplasia and sexual function","volume":"102","author":"Giuliano F.","year":"2008","journal-title":"BJU Int"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93140-5"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.1994.tb09187.x","article-title":"Long\u2010term treatment of benign prostatic hyperplasia with alfuzosin: a 24\u201030 month survey","volume":"74","author":"Jardin A.","year":"1994","journal-title":"BJU Int"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500253"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.05.034"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04252.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-004-0047-1"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00754.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.12.080"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.ijir.3901554","article-title":"Effects of alfuzosin 10\u2009mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia","volume":"19","author":"Rosen R.","year":"2007","journal-title":"Int J Impot Res"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06171.x"}],"container-title":["The Kaohsiung Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1607551X12000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1607551X12000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.kjms.2012.02.013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.kjms.2012.02.013","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.kjms.2012.02.013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:39:07Z","timestamp":1772966347000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1016\/j.kjms.2012.02.013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,12]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1016\/j.kjms.2012.02.013"],"URL":"https:\/\/doi.org\/10.1016\/j.kjms.2012.02.013","archive":["Portico"],"relation":{},"ISSN":["1607-551X","2410-8650"],"issn-type":[{"value":"1607-551X","type":"print"},{"value":"2410-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,12]]}}}